Literature DB >> 20038643

Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis.

Tatsusada Okuno1, Yuji Nakatsuji, Masayuki Moriya, Hyota Takamatsu, Satoshi Nojima, Noriko Takegahara, Toshihiko Toyofuku, Yukinobu Nakagawa, Sujin Kang, Roland H Friedel, Saburo Sakoda, Hitoshi Kikutani, Atsushi Kumanogoh.   

Abstract

Although semaphorins were originally identified as axonal guidance molecules during neuronal development, it is emerging that several semaphorins play crucial roles in various phases of immune responses. Sema4D/CD100, a class IV semaphorin, has been shown to be involved in the nervous and immune systems through its receptors plexin-B1 and CD72, respectively. However, the involvement of Sema4D in neuroinflammation still remains unclear. We found that Sema4D promoted inducible NO synthase expression by primary mouse microglia, the effects of which were abolished in plexin-B1-deficient but not in CD72-deficient microglia. In addition, during the development of experimental autoimmune encephalomyelitis (EAE), which was induced by immunization with myelin oligodendrocyte glycoprotein-derived peptides, we observed that the expression of Sema4D and plexin-B1 was induced in infiltrating mononuclear cells and microglia, respectively. Consistent with these expression profiles, when myelin oligodendrocyte glycoprotein-specific T cells derived from wild-type mice were adoptively transferred into plexin-B1-deficient mice or bone marrow chimera mice with plexin-B1-deficient CNS resident cells, the development of EAE was considerably attenuated. Furthermore, blocking Abs against Sema4D significantly inhibited neuroinflammation during EAE development. Collectively, our findings demonstrate the role of Sema4D-plexin-B1 interactions in the activation of microglia and provide their pathologic significance in neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20038643     DOI: 10.4049/jimmunol.0903302

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

Review 1.  Regulation of immune cell responses by semaphorins and their receptors.

Authors:  Hyota Takamatsu; Tatsusada Okuno; Atsushi Kumanogoh
Journal:  Cell Mol Immunol       Date:  2010-02-01       Impact factor: 11.530

Review 2.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.

Authors:  Prasanta K Hota; Matthias Buck
Journal:  Cell Mol Life Sci       Date:  2012-06-29       Impact factor: 9.261

3.  Suppression of bone formation by osteoclastic expression of semaphorin 4D.

Authors:  Takako Negishi-Koga; Masahiro Shinohara; Noriko Komatsu; Haruhiko Bito; Tatsuhiko Kodama; Roland H Friedel; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2011-10-23       Impact factor: 53.440

Review 4.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

Review 5.  Semaphorins and plexins as therapeutic targets.

Authors:  Thomas Worzfeld; Stefan Offermanns
Journal:  Nat Rev Drug Discov       Date:  2014-08       Impact factor: 84.694

Review 6.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 7.  Biology and function of neuroimmune semaphorins 4A and 4D.

Authors:  EusebiusHenry Nkyimbeng-Takwi; Svetlana P Chapoval
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

Review 8.  Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.

Authors:  Deepa Dash; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 9.  Current advancements in promoting remyelination in multiple sclerosis.

Authors:  David Kremer; Rainer Akkermann; Patrick Küry; Ranjan Dutta
Journal:  Mult Scler       Date:  2018-10-01       Impact factor: 6.312

10.  Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.

Authors:  Rania H Younis; Kyu Lee Han; Tonya J Webb
Journal:  J Immunol       Date:  2016-01-06       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.